L’Oréal first half 2008
This article was originally published in The Rose Sheet
Executive Summary
Consumer products division achieved growth of 5.7% on a like-for-like basis to $6.82 bil., boosted by the "resounding success" of L'Oreal Paris' Skin Genesis, Maybelline New York's Mineral Power foundation and new formulas for Define-A-Lash mascara end SuperStay lipstick, firm says. Revenue of the luxury products unit increased 4.9% to $2.87 bil., reflecting the success of Lancome anti-aging skin care and the launch of several men's products. On a regional basis, North American sales fell 0.5% to $2.86 bil. for the period; however, the market did experience an "upturn" due in part to the consumer products division, which is "strengthening its leadership" on the success of L'Oréal Paris' Infallible Lip and Bare Natural products and Maybelline's Mineral Power foundation, firm notes. Western Europe sales grew 1.3% to $6.01 bil...
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.